Cargando…

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models

AIM: To investigate the effects of plecanatide and dolcanatide on maintenance of paracellular permeability, integrity of tight junctions and on suppression of visceral hypersensitivity. METHODS: Transport of fluorescein isothiocyanate (FITC)-dextran was measured to assess permeability across cell mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulete, Illona-Marie, Thadi, Anusha, Beaufrand, Catherine, Patwa, Viren, Joshi, Apoorva, Foss, John A, Eddy, E Priya, Eutamene, Helene, Palejwala, Vaseem A, Theodorou, Vassilia, Shailubhai, Kunwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937206/
https://www.ncbi.nlm.nih.gov/pubmed/29740204
http://dx.doi.org/10.3748/wjg.v24.i17.1888
_version_ 1783320588251561984
author Boulete, Illona-Marie
Thadi, Anusha
Beaufrand, Catherine
Patwa, Viren
Joshi, Apoorva
Foss, John A
Eddy, E Priya
Eutamene, Helene
Palejwala, Vaseem A
Theodorou, Vassilia
Shailubhai, Kunwar
author_facet Boulete, Illona-Marie
Thadi, Anusha
Beaufrand, Catherine
Patwa, Viren
Joshi, Apoorva
Foss, John A
Eddy, E Priya
Eutamene, Helene
Palejwala, Vaseem A
Theodorou, Vassilia
Shailubhai, Kunwar
author_sort Boulete, Illona-Marie
collection PubMed
description AIM: To investigate the effects of plecanatide and dolcanatide on maintenance of paracellular permeability, integrity of tight junctions and on suppression of visceral hypersensitivity. METHODS: Transport of fluorescein isothiocyanate (FITC)-dextran was measured to assess permeability across cell monolayers and rat colon tissues. Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy. Anti-nociceptive activity of these agonists was evaluated in trinitrobenzene sulfonic acid (TNBS)-induced inflammatory as well as in non-inflammatory partial restraint stress (PRS) rat models. Statistical significance between the treatment groups in the permeability studies were evaluated using unpaired t-tests. RESULTS: Treatment of T84 and Caco-2 monolayers with lipopolysaccharide (LPS) rapidly increased permeability, which was effectively suppressed when monolayers were also treated with plecanatide or dolcanatide. Similarly, when T84 and Caco-2 monolayers were treated with LPS, cell surface localization of tight junction proteins occludin and ZO-1 was severely disrupted. When cell monolayers were treated with LPS in the presence of plecanatide or dolcanatide, occludin and ZO-1 were localized at the cell surface of adjoining cells, similar to that observed for vehicle treated cells. Treatment of cell monolayers with plecanatide or dolcanatide without LPS did not alter permeability, integrity of tight junctions and cell surface localization of either of the tight junction proteins. In rat visceral hypersensitivity models, both agonists suppressed the TNBS-induced increase in abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity, and both agonists also reduced colonic hypersensitivity in the PRS model. CONCLUSION: Our results suggest that activation of GC-C signaling might be involved in maintenance of barrier function, possibly through regulating normal localization of tight junction proteins. Consistent with these findings, plecanatide and dolcanatide showed potent anti-nociceptive activity in rat visceral hypersensitivity models. These results imply that activation of GC-C signaling may be an attractive therapeutic approach to treat functional constipation disorders and inflammatory gastrointestinal conditions.
format Online
Article
Text
id pubmed-5937206
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-59372062018-05-08 Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models Boulete, Illona-Marie Thadi, Anusha Beaufrand, Catherine Patwa, Viren Joshi, Apoorva Foss, John A Eddy, E Priya Eutamene, Helene Palejwala, Vaseem A Theodorou, Vassilia Shailubhai, Kunwar World J Gastroenterol Basic Study AIM: To investigate the effects of plecanatide and dolcanatide on maintenance of paracellular permeability, integrity of tight junctions and on suppression of visceral hypersensitivity. METHODS: Transport of fluorescein isothiocyanate (FITC)-dextran was measured to assess permeability across cell monolayers and rat colon tissues. Effects of plecanatide and dolcanatide on the integrity of tight junctions in Caco-2 and T84 monolayers and on the expression and localization of occludin and zonula occludens-1 (ZO-1) were examined by immunofluorescence microscopy. Anti-nociceptive activity of these agonists was evaluated in trinitrobenzene sulfonic acid (TNBS)-induced inflammatory as well as in non-inflammatory partial restraint stress (PRS) rat models. Statistical significance between the treatment groups in the permeability studies were evaluated using unpaired t-tests. RESULTS: Treatment of T84 and Caco-2 monolayers with lipopolysaccharide (LPS) rapidly increased permeability, which was effectively suppressed when monolayers were also treated with plecanatide or dolcanatide. Similarly, when T84 and Caco-2 monolayers were treated with LPS, cell surface localization of tight junction proteins occludin and ZO-1 was severely disrupted. When cell monolayers were treated with LPS in the presence of plecanatide or dolcanatide, occludin and ZO-1 were localized at the cell surface of adjoining cells, similar to that observed for vehicle treated cells. Treatment of cell monolayers with plecanatide or dolcanatide without LPS did not alter permeability, integrity of tight junctions and cell surface localization of either of the tight junction proteins. In rat visceral hypersensitivity models, both agonists suppressed the TNBS-induced increase in abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity, and both agonists also reduced colonic hypersensitivity in the PRS model. CONCLUSION: Our results suggest that activation of GC-C signaling might be involved in maintenance of barrier function, possibly through regulating normal localization of tight junction proteins. Consistent with these findings, plecanatide and dolcanatide showed potent anti-nociceptive activity in rat visceral hypersensitivity models. These results imply that activation of GC-C signaling may be an attractive therapeutic approach to treat functional constipation disorders and inflammatory gastrointestinal conditions. Baishideng Publishing Group Inc 2018-05-07 2018-05-07 /pmc/articles/PMC5937206/ /pubmed/29740204 http://dx.doi.org/10.3748/wjg.v24.i17.1888 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Boulete, Illona-Marie
Thadi, Anusha
Beaufrand, Catherine
Patwa, Viren
Joshi, Apoorva
Foss, John A
Eddy, E Priya
Eutamene, Helene
Palejwala, Vaseem A
Theodorou, Vassilia
Shailubhai, Kunwar
Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title_full Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title_fullStr Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title_full_unstemmed Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title_short Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
title_sort oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-c in rat models
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937206/
https://www.ncbi.nlm.nih.gov/pubmed/29740204
http://dx.doi.org/10.3748/wjg.v24.i17.1888
work_keys_str_mv AT bouleteillonamarie oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT thadianusha oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT beaufrandcatherine oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT patwaviren oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT joshiapoorva oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT fossjohna oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT eddyepriya oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT eutamenehelene oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT palejwalavaseema oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT theodorouvassilia oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels
AT shailubhaikunwar oraltreatmentwithplecanatideordolcanatideattenuatesvisceralhypersensitivityviaactivationofguanylatecyclasecinratmodels